search
Back to results

A Study on the Effects of Left Ventricular Unloading in the Setting of VA ECMO Support (REMAP ECMO)

Primary Purpose

Cardiogenic Shock

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Intra-aortic balloon pump
Sponsored by
Erasmus Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiogenic Shock focused on measuring Left ventricular unloading, Venoarterial ExtraCorporeal Membrane Oxygenation (VA ECMO), Cardiogenic shock

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria for the registry backbone: Having received ECMO support for severe circulatory and/or respiratory insufficiency Inclusion Criteria for the LV unloading trial domain (VA ECMO + IABP vs VA ECMO alone): Cardiogenic shock Having received VA ECMO support for severe circulatory (and respiratory insufficiency). Age ≥ 18 years Initiation of LV unloading (IABP or Impella) possible ≤ 8 hours after ECMO initiation Exclusion criteria for the registry backbone Objection to participation in the registry by the patient and/or proxy VA ECMO usage confined to the period during surgery or another intervention (the VA ECMO was removed at the end of the intervention in the operation room). Exclusion criteria for the LV unloading trial domain (VA ECMO + IABP vs VA ECMO alone) No (deferred) informed consent provided by the patient and/or proxy. Pregnancy ECMO usage confined to the period during surgery or another intervention (the ECMO was removed at the end of the intervention). Isolated right ventricular failure (e.g. due to pulmonary embolism). Left ventricular assist device (LVAD), Impella or IABP in situ. Ventricular septal defect or papillary muscle rupture as the cause of shock. Thoracic or abdominal aortic dissection. Moderate or severe aortic regurgitation Mechanical prosthesis in mitral valve position

Sites / Locations

  • Amphia hospital
  • Catharina hospital
  • Amsterdam University Medical Center
  • Antonius hospital
  • Haga ziekenhuis
  • Leiden University Medical Center
  • Erasmus Medical CenterRecruiting
  • University Medical Center Utrecht

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

IABP unloading arm

ECMO alone arm

Arm Description

This group of patients will receive an intra-aortic balloon pump (IABP) as an adjunct to VA ECMO support. When allocated to the IABP unloading arm, patients must receive an IABP within 8 hours after VA ECMO initiation.

This group of patients will receive VA ECMO support without left ventricular unloading device after randomization.

Outcomes

Primary Outcome Measures

ECMO weaning success
Proportion of patients successfully weaned from VA ECMO at 30 days being defined by; a) being alive, b) without ECMO, IABP or Impella support, and c) not having received a heart transplantation or left ventricular assist device (LVAD).

Secondary Outcome Measures

Treatment failure
The proportion of patients in whom LV unloading therapy was escalated. Escalation is defined by the insertion of an IABP (only in the VA ECMO alone arm), or Impella or left vent (IABP unloading arm or VA ECMO alone arm).
30 day, 90 day and 1 year mortality
Mortality rate at 30 days, 90 days and 1 year after ECMO initiation
ECMO support duration
The duration of ECMO support in days
Major bleeding events
The occurrence of major bleeding events (fatal, in a critical area (intracranial, intraspinal, or intraocular), requiring intervention (coiling or surgery) and/or transfusion of ≥3 packed cells) until 30 days after VA ECMO initiation.
Unplanned surgical or catheter based intervention of the leg(s)
Unplanned surgical or catheter based intervention of the leg(s) in which ECMO and/or IABP or Impella was inserted until 30 days after ECMO initiation.
Time to lactate normalization
Time to lactate normalization (<2 mmol/L).
Time to first negative net fluid balance
Time to first negative net fluid balance (calculated per 24 hours).
The occurrence of continuous venovenous hemofiltration initiation during ECMO support
The occurrence of continuous venovenous hemofiltration (dialysis) (CVVH(D)) initiation during ECMO support.
Course in PF ratio
Course in PaO2/FiO2 (PF) ratio (PaO2 divided by FiO2 provided)
Duration of mechanical ventilation.
Duration of mechanical ventilation. Patients on mechanical ventilation via tracheostomy need to be 24 hours free of mechanical ventilation.
Left ventricular ejection fraction 30 days after ECMO initiation.
Left ventricular ejection fraction 30 days after ECMO initiation.
Time course in vasoactive inotropic score (VIS) during ECMO support
Time course in vasoactive inotropic score (VIS) during ECMO support
Time course in NT-pro BNP during ECMO support.
Time course in NT-pro BNP during ECMO support.
Quality of life at 1 year
Quality of life on basis of EQ5D questionnaires
Total health care costs
Total healthcare costs in euros are determined by using the International Medical Consumption Questionnaire (iMCQ) and the calculated costs after 6 and 12 months of follow up
Hospital readmission rate
The number of hospital readmissions based on the information provided in the international Medical Consumption Questionnaire (iMCQ)

Full Information

First Posted
June 12, 2023
Last Updated
June 21, 2023
Sponsor
Erasmus Medical Center
Collaborators
Dutch Heart Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT05913622
Brief Title
A Study on the Effects of Left Ventricular Unloading in the Setting of VA ECMO Support
Acronym
REMAP ECMO
Official Title
Randomized Embedded Multifactorial Adaptive Platform in ExtraCorporeal Membrane Oxygenation (REMAP ECMO) - Left Ventricular Unloading Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 8, 2023 (Actual)
Primary Completion Date
July 1, 2027 (Anticipated)
Study Completion Date
June 1, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center
Collaborators
Dutch Heart Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
REMAP ECMO is a registry based platform in which multiple response adaptive randomized clinical trials (trial domains) will be embedded. These trial domains will, in a perpetual way, study the effects of a range of patient management strategies which aim to improve VA ECMO weaning success. A first trial domain will address the effects of left ventricular (LV) unloading through intra-aortic balloon pumping on weaning succes in VA ECMO supported patients.
Detailed Description
ExtraCorporeal Membrane Oxygenation (ECMO) is increasingly used but remains associated with high weaning failure- and mortality- rates. This seems in part attributable to a knowledge gap on how to properly manage ECMO and its related therapies as current knowledge and treatment protocols are based on observational studies and expert opinions. The "Randomized Embedded Multifactorial Adaptive Platform in ECMO" (REMAP ECMO) study was developed to study, in an efficient and randomized way, different ECMO related patient management issues and will consist of two parts: A patient registry that will serve for quality monitoring and observational studies of ECMO patients being treated in participating centers. Embedded within the registry, multiple response adaptive randomized clinical trials (trial domains) which aim to evaluate the effectiveness of a range of therapeutic interventions on ECMO weaning success. These interventions all have in common that they are all already used in ECMO care but their use depends on center and/or doctors preferences as no high quality (randomized) evidence guiding their indication, timing and management exists. A first trial domain to be initiated within the REMAP ECMO platform will address the effects of different left ventricular (LV) unloading techniques, through application of an intra-aortic balloon pump (IABP), on weaning success in the setting of venoarterial (VA) ECMO. The rationale of this trial domain is based on the increase in LV loading conditions, as induced by VA ECMO, which could lead to pulmonary edema, intracardiac thrombosis and even death. These serious sequelae could possibly be prevented by adding IABP as adjunct to VA ECMO therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiogenic Shock
Keywords
Left ventricular unloading, Venoarterial ExtraCorporeal Membrane Oxygenation (VA ECMO), Cardiogenic shock

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains
Masking
None (Open Label)
Masking Description
No masking is possible as the device is visible after placement.
Allocation
Randomized
Enrollment
430 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IABP unloading arm
Arm Type
Experimental
Arm Description
This group of patients will receive an intra-aortic balloon pump (IABP) as an adjunct to VA ECMO support. When allocated to the IABP unloading arm, patients must receive an IABP within 8 hours after VA ECMO initiation.
Arm Title
ECMO alone arm
Arm Type
No Intervention
Arm Description
This group of patients will receive VA ECMO support without left ventricular unloading device after randomization.
Intervention Type
Device
Intervention Name(s)
Intra-aortic balloon pump
Other Intervention Name(s)
IABP
Intervention Description
An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
Primary Outcome Measure Information:
Title
ECMO weaning success
Description
Proportion of patients successfully weaned from VA ECMO at 30 days being defined by; a) being alive, b) without ECMO, IABP or Impella support, and c) not having received a heart transplantation or left ventricular assist device (LVAD).
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Treatment failure
Description
The proportion of patients in whom LV unloading therapy was escalated. Escalation is defined by the insertion of an IABP (only in the VA ECMO alone arm), or Impella or left vent (IABP unloading arm or VA ECMO alone arm).
Time Frame
During ECMO support
Title
30 day, 90 day and 1 year mortality
Description
Mortality rate at 30 days, 90 days and 1 year after ECMO initiation
Time Frame
30 days, 90 days and 1 year after ECMO initiation
Title
ECMO support duration
Description
The duration of ECMO support in days
Time Frame
Until 30 days after ECMO initiation
Title
Major bleeding events
Description
The occurrence of major bleeding events (fatal, in a critical area (intracranial, intraspinal, or intraocular), requiring intervention (coiling or surgery) and/or transfusion of ≥3 packed cells) until 30 days after VA ECMO initiation.
Time Frame
Until 30 days after ECMO initiation
Title
Unplanned surgical or catheter based intervention of the leg(s)
Description
Unplanned surgical or catheter based intervention of the leg(s) in which ECMO and/or IABP or Impella was inserted until 30 days after ECMO initiation.
Time Frame
Until 30 days after ECMO initiation
Title
Time to lactate normalization
Description
Time to lactate normalization (<2 mmol/L).
Time Frame
Until 30 days after ECMO initiation
Title
Time to first negative net fluid balance
Description
Time to first negative net fluid balance (calculated per 24 hours).
Time Frame
Until 30 days after ECMO initiation
Title
The occurrence of continuous venovenous hemofiltration initiation during ECMO support
Description
The occurrence of continuous venovenous hemofiltration (dialysis) (CVVH(D)) initiation during ECMO support.
Time Frame
Until 30 days after ECMO initiation
Title
Course in PF ratio
Description
Course in PaO2/FiO2 (PF) ratio (PaO2 divided by FiO2 provided)
Time Frame
Until 30 days after ECMO initiation.
Title
Duration of mechanical ventilation.
Description
Duration of mechanical ventilation. Patients on mechanical ventilation via tracheostomy need to be 24 hours free of mechanical ventilation.
Time Frame
Until 30 days after ECMO initiation.
Title
Left ventricular ejection fraction 30 days after ECMO initiation.
Description
Left ventricular ejection fraction 30 days after ECMO initiation.
Time Frame
At 30 days after ECMO initiation.
Title
Time course in vasoactive inotropic score (VIS) during ECMO support
Description
Time course in vasoactive inotropic score (VIS) during ECMO support
Time Frame
Until 30 days after ECMO initiation.
Title
Time course in NT-pro BNP during ECMO support.
Description
Time course in NT-pro BNP during ECMO support.
Time Frame
Until 30 days after ECMO initiation.
Title
Quality of life at 1 year
Description
Quality of life on basis of EQ5D questionnaires
Time Frame
1 year after ECMO initiation
Title
Total health care costs
Description
Total healthcare costs in euros are determined by using the International Medical Consumption Questionnaire (iMCQ) and the calculated costs after 6 and 12 months of follow up
Time Frame
6 and 12 months after ECMO initiation
Title
Hospital readmission rate
Description
The number of hospital readmissions based on the information provided in the international Medical Consumption Questionnaire (iMCQ)
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria for the registry backbone: Having received ECMO support for severe circulatory and/or respiratory insufficiency Inclusion Criteria for the LV unloading trial domain (VA ECMO + IABP vs VA ECMO alone): Cardiogenic shock Having received VA ECMO support for severe circulatory (and respiratory insufficiency). Age ≥ 18 years Initiation of LV unloading (IABP or Impella) possible ≤ 8 hours after ECMO initiation Exclusion criteria for the registry backbone Objection to participation in the registry by the patient and/or proxy VA ECMO usage confined to the period during surgery or another intervention (the VA ECMO was removed at the end of the intervention in the operation room). Exclusion criteria for the LV unloading trial domain (VA ECMO + IABP vs VA ECMO alone) No (deferred) informed consent provided by the patient and/or proxy. Pregnancy ECMO usage confined to the period during surgery or another intervention (the ECMO was removed at the end of the intervention). Isolated right ventricular failure (e.g. due to pulmonary embolism). Left ventricular assist device (LVAD), Impella or IABP in situ. Ventricular septal defect or papillary muscle rupture as the cause of shock. Thoracic or abdominal aortic dissection. Moderate or severe aortic regurgitation Mechanical prosthesis in mitral valve position
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Myrthe van Steenwijk
Phone
+31627535136
Email
m.p.j.vansteenwijk@erasmusmc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Christiaan Meuwese
Phone
+31631135752
Email
c.meuwese@erasmusmc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christiaan Meuwese
Organizational Affiliation
Erasmus Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amphia hospital
City
Breda
State/Province
Brabant
ZIP/Postal Code
4818 CK
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Catharina hospital
City
Eindhoven
State/Province
Brabant
ZIP/Postal Code
5623 EJ
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Amsterdam University Medical Center
City
Amsterdam
State/Province
Noord Holland
ZIP/Postal Code
1105 AZ
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Antonius hospital
City
Nieuwegein
State/Province
Utrecht
ZIP/Postal Code
3435 CM
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Haga ziekenhuis
City
Den Haag
State/Province
Zuid Holland
ZIP/Postal Code
2545 AA
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Leiden University Medical Center
City
Leiden
State/Province
Zuid Holland
ZIP/Postal Code
2333 ZA
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Erasmus Medical Center
City
Rotterdam
State/Province
Zuid Holland
ZIP/Postal Code
3015 GD
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Myrthe V Steenwijk
Phone
+31627535136
Email
m.p.j.vansteenwijk@erasmusmc.nl
Facility Name
University Medical Center Utrecht
City
Utrecht
ZIP/Postal Code
3584 CX
Country
Netherlands
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Citations:
PubMed Identifier
24210621
Citation
Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, Esmailian F, Azarbal B. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. 2014 Feb;97(2):610-6. doi: 10.1016/j.athoracsur.2013.09.008. Epub 2013 Nov 8.
Results Reference
background
PubMed Identifier
29655828
Citation
Keebler ME, Haddad EV, Choi CW, McGrane S, Zalawadiya S, Schlendorf KH, Brinkley DM, Danter MR, Wigger M, Menachem JN, Shah A, Lindenfeld J. Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock. JACC Heart Fail. 2018 Jun;6(6):503-516. doi: 10.1016/j.jchf.2017.11.017. Epub 2018 Apr 11.
Results Reference
background
PubMed Identifier
33032450
Citation
Schrage B, Becher PM, Bernhardt A, Bezerra H, Blankenberg S, Brunner S, Colson P, Cudemus Deseda G, Dabboura S, Eckner D, Eden M, Eitel I, Frank D, Frey N, Funamoto M, Gossling A, Graf T, Hagl C, Kirchhof P, Kupka D, Landmesser U, Lipinski J, Lopes M, Majunke N, Maniuc O, McGrath D, Mobius-Winkler S, Morrow DA, Mourad M, Noel C, Nordbeck P, Orban M, Pappalardo F, Patel SM, Pauschinger M, Pazzanese V, Reichenspurner H, Sandri M, Schulze PC, H G Schwinger R, Sinning JM, Aksoy A, Skurk C, Szczanowicz L, Thiele H, Tietz F, Varshney A, Wechsler L, Westermann D. Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study. Circulation. 2020 Dec;142(22):2095-2106. doi: 10.1161/CIRCULATIONAHA.120.048792. Epub 2020 Oct 9.
Results Reference
background
PubMed Identifier
30586721
Citation
Thiele H, Zeymer U, Thelemann N, Neumann FJ, Hausleiter J, Abdel-Wahab M, Meyer-Saraei R, Fuernau G, Eitel I, Hambrecht R, Bohm M, Werdan K, Felix SB, Hennersdorf M, Schneider S, Ouarrak T, Desch S, de Waha-Thiele S; IABP-SHOCK II Trial (Intraaortic Balloon Pump in Cardiogenic Shock II) Investigators; IABP-SHOCK II Investigators. Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial. Circulation. 2019 Jan 15;139(3):395-403. doi: 10.1161/CIRCULATIONAHA.118.038201. Epub 2018 Nov 11.
Results Reference
background
PubMed Identifier
35361346
Citation
Grandin EW, Nunez JI, Willar B, Kennedy K, Rycus P, Tonna JE, Kapur NK, Shaefi S, Garan AR. Mechanical Left Ventricular Unloading in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation. J Am Coll Cardiol. 2022 Apr 5;79(13):1239-1250. doi: 10.1016/j.jacc.2022.01.032.
Results Reference
background
PubMed Identifier
30765031
Citation
Russo JJ, Aleksova N, Pitcher I, Couture E, Parlow S, Faraz M, Visintini S, Simard T, Di Santo P, Mathew R, So DY, Takeda K, Garan AR, Karmpaliotis D, Takayama H, Kirtane AJ, Hibbert B. Left Ventricular Unloading During Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock. J Am Coll Cardiol. 2019 Feb 19;73(6):654-662. doi: 10.1016/j.jacc.2018.10.085.
Results Reference
background
PubMed Identifier
31656647
Citation
Na SJ, Yang JH, Yang JH, Sung K, Choi JO, Hahn JY, Jeon ES, Cho YH. Left heart decompression at venoarterial extracorporeal membrane oxygenation initiation in cardiogenic shock: prophylactic versus therapeutic strategy. J Thorac Dis. 2019 Sep;11(9):3746-3756. doi: 10.21037/jtd.2019.09.35.
Results Reference
background

Learn more about this trial

A Study on the Effects of Left Ventricular Unloading in the Setting of VA ECMO Support

We'll reach out to this number within 24 hrs